{"id":"symlin-pramlintide","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Anorexia"},{"rate":"15–30","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2103758","moleculeType":"Protein","molecularWeight":"3949.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pramlintide mimics amylin, a hormone co-secreted with insulin that regulates postprandial glucose excursions. It acts on amylin receptors to delay gastric emptying, suppress glucagon secretion during the postprandial period, and promote satiety. These combined effects reduce postmeal blood glucose spikes in patients with type 1 and type 2 diabetes.","oneSentence":"Pramlintide is an amylin analog that slows gastric emptying, reduces postprandial glucagon secretion, and increases satiety to improve blood glucose control in diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:26.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus (adjunct to insulin therapy)"},{"name":"Type 2 diabetes mellitus (adjunct to insulin therapy)"}]},"trialDetails":[{"nctId":"NCT06422325","phase":"NA","title":"Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2024-07-12","conditions":"Type 1 Diabetes","enrollment":33},{"nctId":"NCT07340788","phase":"NA","title":"Amylin-Induced Migraine Attacks Without Aura","status":"NOT_YET_RECRUITING","sponsor":"Danish Headache Center","startDate":"2026-02","conditions":"Headache Disorders, Primary, Headache Disorders, Brain Diseases","enrollment":21},{"nctId":"NCT07340775","phase":"NA","title":"Hypersensitivity to Amylin in Post-Traumatic Headache","status":"NOT_YET_RECRUITING","sponsor":"Danish Headache Center","startDate":"2026-02","conditions":"Headache Disorders, Secondary, Brain Diseases, Headache Disorders","enrollment":21},{"nctId":"NCT03560960","phase":"EARLY_PHASE1","title":"Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston University","startDate":"2020-02-04","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":57},{"nctId":"NCT06619015","phase":"PHASE2, PHASE3","title":"Tailoring Obesity Treatment Trial","status":"SUSPENDED","sponsor":"Esbjerg Hospital - University Hospital of Southern Denmark","startDate":"2025-09","conditions":"Obesity, Appetite Regulation, PreDiabetes","enrollment":40},{"nctId":"NCT06046417","phase":"PHASE2, PHASE3","title":"A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2023-11-30","conditions":"type1diabetes, Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT04074317","phase":"PHASE2","title":"Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D","status":"COMPLETED","sponsor":"Xeris Pharmaceuticals","startDate":"2019-08-22","conditions":"Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus","enrollment":18},{"nctId":"NCT06186063","phase":"NA","title":"The Role of Amylin in Bone Metabolism","status":"UNKNOWN","sponsor":"Filip Krag Knop","startDate":"2024-02-12","conditions":"Bone Diseases, Metabolic, Type 1 Diabetes","enrollment":20},{"nctId":"NCT05199714","phase":"NA","title":"A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-02-21","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT01841359","phase":"PHASE4","title":"Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2010-02-02","conditions":"Hypoglycemia, Evidence of Previous Gastric Surgery","enrollment":22},{"nctId":"NCT04252612","phase":"EARLY_PHASE1","title":"Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study","status":"WITHDRAWN","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-01-30","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT04243629","phase":"NA","title":"Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes","status":"UNKNOWN","sponsor":"McGill University","startDate":"2021-11-12","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia","enrollment":26},{"nctId":"NCT00691158","phase":"NA","title":"A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2006-01","conditions":"Obesity","enrollment":10},{"nctId":"NCT04163874","phase":"NA","title":"Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-02-14","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial","enrollment":36},{"nctId":"NCT03547427","phase":"NA","title":"Glucagon Counterregulation in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-05-20","conditions":"Type 1 Diabetes Mellitus","enrollment":13},{"nctId":"NCT04972175","phase":"PHASE1","title":"Safety and Efficacy of BC LisPram","status":"UNKNOWN","sponsor":"Michael Tsoukas","startDate":"2021-07-28","conditions":"Type1 Diabetes Mellitus","enrollment":16},{"nctId":"NCT00732147","phase":"NA","title":"Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2009-04","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT03800875","phase":"PHASE2","title":"Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting","status":"COMPLETED","sponsor":"McGill University","startDate":"2019-02-08","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT03993366","phase":"NA","title":"Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement","status":"COMPLETED","sponsor":"McGill University","startDate":"2019-03-01","conditions":"Type 1 Diabetes Mellitus","enrollment":8},{"nctId":"NCT03981627","phase":"PHASE1, PHASE2","title":"A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2019-06-06","conditions":"Type 1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT00790699","phase":"NA","title":"Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port","status":"TERMINATED","sponsor":"Texas Diabetes & Endocrinology, P.A.","startDate":"2009-08","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":31},{"nctId":"NCT03598075","phase":"NA","title":"Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2018-07-01","conditions":"Migraine Without Aura","enrollment":36},{"nctId":"NCT02814123","phase":"PHASE2","title":"Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University","startDate":"2017-01-13","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT03916640","phase":"PHASE1","title":"A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2019-01-04","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT03512236","phase":"PHASE1","title":"A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2018-04-25","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00505882","phase":"PHASE4","title":"Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-07","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT00690235","phase":"PHASE4","title":"Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-11","conditions":"Schizophrenia, Schizoaffective Disorder, Diabetes","enrollment":33},{"nctId":"NCT02500979","phase":"PHASE1","title":"Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-17","conditions":"Type 1 Diabetes Mellitus","enrollment":34},{"nctId":"NCT01165944","phase":"PHASE1, PHASE2","title":"Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2009-08","conditions":"Diabetes Mellitus","enrollment":""},{"nctId":"NCT00442767","phase":"PHASE4","title":"Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2007-02","conditions":"Type 1 Diabetes Mellitus","enrollment":8},{"nctId":"NCT01269047","phase":"PHASE4","title":"Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-08","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT01269008","phase":"PHASE1","title":"Closed Loop System With Pramlintide Versus Exenatide","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2010-12","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT00950677","phase":"PHASE4","title":"The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00206258","phase":"PHASE3","title":"The Role of Amylin and Glucagon in T1DM","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2002-07","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT00206297","phase":"PHASE3","title":"The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2003-10","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT00291772","phase":"PHASE4","title":"Continuous Subcutaneous Infusion of Pramlintide and Insulin","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-01","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT00042601","phase":"PHASE2","title":"Evaluation of the Effect of Pramlintide on Satiety and Food Intake","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-07","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":51},{"nctId":"NCT00107107","phase":"PHASE3","title":"Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-11","conditions":"Diabetes Mellitus, Type 1","enrollment":190},{"nctId":"NCT00042471","phase":"PHASE2","title":"Evaluation of the Bioavailability of Pramlintide","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-06","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":75},{"nctId":"NCT00042458","phase":"PHASE3","title":"Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-04","conditions":"Diabetes Mellitus, Type 1","enrollment":296},{"nctId":"NCT00842075","phase":"NA","title":"Pramlintide in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2006-12","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT00444561","phase":"PHASE2","title":"Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-08","conditions":"Overweight, Obesity","enrollment":184},{"nctId":"NCT00189514","phase":"PHASE2","title":"A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-09","conditions":"Obesity","enrollment":210},{"nctId":"NCT00108004","phase":"PHASE3","title":"Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":400},{"nctId":"NCT00044707","phase":"PHASE2","title":"Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-08","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":24},{"nctId":"NCT01235741","phase":"PHASE2","title":"A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2011-01","conditions":"Obesity","enrollment":213},{"nctId":"NCT00819234","phase":"PHASE2","title":"Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Obesity","enrollment":274},{"nctId":"NCT00673387","phase":"PHASE2","title":"Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Overweight, Obesity","enrollment":636},{"nctId":"NCT00392925","phase":"PHASE2","title":"A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-10","conditions":"Overweight, Obesity","enrollment":177},{"nctId":"NCT00467649","phase":"PHASE4","title":"A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT00112021","phase":"PHASE2","title":"A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Obesity","enrollment":400},{"nctId":"NCT00240253","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Type 2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT00229658","phase":"","title":"An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-09","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":1297},{"nctId":"NCT00402077","phase":"PHASE2","title":"A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-11","conditions":"Overweight, Obesity","enrollment":258},{"nctId":"NCT00313183","phase":"PHASE2","title":"A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Type 1 Diabetes Mellitus","enrollment":12},{"nctId":"NCT01708044","phase":"PHASE1","title":"Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11","conditions":"Type 1 Diabetes","enrollment":32},{"nctId":"NCT01434862","phase":"NA","title":"Pramlintide Combined With Model Predictive Control Algorithm","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2011-02","conditions":"Type 1 Diabetes Mellitus","enrollment":2},{"nctId":"NCT01839370","phase":"NA","title":"Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2013-07","conditions":"Diabetes Mellitus, Type 1","enrollment":9},{"nctId":"NCT00502138","phase":"PHASE4","title":"A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University Diabetes & Endocrine Consultants","startDate":"2007-07","conditions":"IDDM","enrollment":12},{"nctId":"NCT01137695","phase":"PHASE3","title":"Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Cheryl Rosenfeld, DO","startDate":"2010-05","conditions":"Type 2 Diabetes Mellitus","enrollment":40},{"nctId":"NCT00460304","phase":"NA","title":"The Effect of Pramlintide on Meal Time Insulin Bolus","status":"COMPLETED","sponsor":"Diabetes Care Center","startDate":"2007-09","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT00489645","phase":"NA","title":"Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2005-01","conditions":"Type 1 Diabetes","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":442,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Symlin (pramlintide)","genericName":"Symlin (pramlintide)","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pramlintide is an amylin analog that slows gastric emptying, reduces postprandial glucagon secretion, and increases satiety to improve blood glucose control in diabetes. Used for Type 1 diabetes mellitus (adjunct to insulin therapy), Type 2 diabetes mellitus (adjunct to insulin therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}